openPR Logo
Press release

Rare Disease Drugs Market - Competitive Analysis Key Findings with Worldwide Top Companies Novartis AG,Hoffmann-La Roche, Celgene,Bristol-Myers,Squibb Company, Shire, Pfizer

05-30-2019 09:46 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Coherent Market Insights

Rare Disease Drugs

Rare Disease Drugs

Rare diseases or orphan diseases are conditions that affect a small percentage of population at any given time. Orphan drug designation is given to the drugs indicated for the treatment of rare diseases. According to the U.S. Food & Drug Administration (FDA), an orphan disease is defined as a disease or condition affecting less than 200,000 people in the country. Orphan Drugs Act under the U.S. legislation allows manufacturer to request FDA to grant an orphan drug status to drugs intended to treat a rare disease or condition. According to the FDA, 2017, number of orphan drug designation requests have steadily increased over the past few years.

The global rare disease drugs market was not considered lucrative until recently, owing to various uncertainties associated with these diseases. Small percentage of affected population provided limited opportunity for study. Moreover, diseases were poorly understood, owing to huge differentiation and heterogeneity among the group of diseases which discouraged manufacturers to address unmet needs in this space. However, introduction of some highly priced orphan drugs e.g. spinal muscular atrophy drug Spinraza priced at US$ 125,000 per vial, and high unmet needs has drawn attention of manufacturers towards rare disease drugs market.

The total revenue of top 10 global rare disease drugs market for 2016 accounted for US$ 62.5 billion.

Request A Sample Copy:
https://www.coherentmarketinsights.com/insight/request-sample/1200

Competitive Analysis of top 10 organizations in the global rare disease drugs market

Top 10 organizations in the global rare disease drugs market in 2016, based on the 2016 revenue include:

Novartis AG
Hoffmann-La Roche Ltd.
Celgene Corporation
Bristol-Myers Squibb Company
Shire plc
Pfizer, Inc.
Sanofi S.A.
Bayer
Alexion Pharmaceuticals, Inc.
Biogen, Inc.

Novartis AG is a global pharmaceutical organization with a diverse product folio ranging from drug therapies for cancer treatment to ophthalmic products. The company operates business through Innovative Medicines Division, which consists of oncology business unit and Novartis pharmaceutical business units. Innovative medicines Oncology division offers products for oncology diseases and rare diseases, and pharmaceutical business consists of ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic, and established medicines. Novartis lost patent protection for its orphan drug Gleevec for the treatment of chronic myeloid leukemia (CML) in 2015 and Sun Pharma brought out generic Gleevec in 2016 hampering the sales of Novartis for Gleevec.

Celgene Corporation specializes in therapies for cancer treatment and inflammatory diseases which includes drugs such as Revlimid, Pomalyst, and Otezla. The company currently is concentrated on expanding the indication range of the present therapies and has a robust pipeline for oncology conditions. For instance, Revlimid (lenalidomide), in phase III clinical trials for diffuse large B-cell lymphoma, indolent lymphoma, and follicular lymphoma. Furthermore, the company has developed its own target-identification and drug-discovery technology platforms which enable the company to proceed rapidly from target identification and validation to lead identification and optimization.

Shire Plc. became global leader in orphan drug products category (excluding oncology products) in year 2016 and grossed almost US$ 11 billion. The company acquired Baxalta in 2016, and its three therapeutic segments namely hematology, immunology, and oncology. Shire Plc. is also focused on providing therapies for rare diseases as it invested US$ 1.4 billion in research and development. The company had 37 therapies in research and the pipeline has further been strengthened by acquisition of Dyax and Baxalta in 2016.

Global rare disease drugs market is impacted by various key trends which are driven by supply as well as demand side. Wide gap between market needs and potential market offerings is the main driving force behind an increasing interest of the manufacturers towards providing therapies in this segment of the healthcare industry. According to the U.S. Food & Drug Administration (FDA), in 2016, 582 requests for orphan drug designation were filed by the biopharma companies. Furthermore, the sales of orphan drug diseases has been on a rise due to availability of highly effective drug therapies. Moreover, potential drug therapies are present in pipeline for various cancers and rare diseases such as Niraparib by Tesaro, Inc. in phase I for the treatment of ovarian cancer, Emicizumab by Roche in phase III for the treatment of hemophilia, and LentiGlobin by Bluebird Bio in different phases for the treatment of sickle cell anemia and beta-thalassemia major. Positive results from these clinical trials are expected to change the outlook of the global rare disease drugs market over the foreseeable future.

This study provides a detailed competitive landscape and competitive analysis for leading players in this market. This will the aid one in understanding the operations of successful companies in this market and their long term goals.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1200

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rare Disease Drugs Market - Competitive Analysis Key Findings with Worldwide Top Companies Novartis AG,Hoffmann-La Roche, Celgene,Bristol-Myers,Squibb Company, Shire, Pfizer here

News-ID: 1758893 • Views: 335

More Releases from Coherent Market Insights

sodium cyanide market Growth Analysis 2020-2027 | Key Vendors Cyanco, E. I. DuPo …
The Sodium Cyanide Market report released and promoted by CMI draw out historical, existing, and forecast valuation of the Sodium Cyanide industry till 2026. The report highlights the market essentials, opportunities, regional market, Emerging Growth Factors, market challenges, forecast and competitors joined with their market share. The fundamental purpose of Sodium Cyanide Market report is to provide a appropriate and strategic analysis of the Sodium Cyanide industry. Request to Get
Essential Oil Market Expert Guide to Boost the Industry in Global Market Share 2 …
The Essential Oil Market report released and promoted by CMI draw out historical, existing, and forecast valuation of the Essential Oil industry till 2026. The report highlights the market essentials, opportunities, regional market, Emerging Growth Factors, market challenges, forecast and competitors joined with their market share. The fundamental purpose of Essential Oil Market report is to provide a appropriate and strategic analysis of the Essential Oil industry. Request to Get
Vanillin Market Experts Review Report 2020-2027 | Evolva Holding SA, Solvay SA, …
The Vanillin Market report released and promoted by CMI draw out historical, existing, and forecast valuation of the Vanillin industry till 2026. The report highlights the market essentials, opportunities, regional market, Emerging Growth Factors, market challenges, forecast and competitors joined with their market share. The fundamental purpose of Vanillin Market report is to provide a appropriate and strategic analysis of the Vanillin industry. Request to Get the PDF Sample of
Endoscopy Device Market 2020 - 2026 | Insights, Trends, Size By Top Players Arth …
Endoscopy Device Market report provides a thoroughly researched abstract of the key players with considerable shareholdings at a global level regarding demand, sales, and income by providing better products and services. Research Report outlines a forecast for the Endoscopy Device market between 2020 and 2027. In terms of value, the Endoscopy Device industry is expected to register a steady CAGR during the forecast period. The report offers a systematic presentation of

All 5 Releases


More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning